{"transactions":[{"id":1754655,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-26T20:09:29.000Z","date":"2023-10-24","kind":"purchase","planned":false,"acquired":true,"shares":80000,"price":2.5,"value":200000.0,"ownership":{"direct":true},"balance_after":8764232,"source":{"system":"sec-edgar","filing":"0001209191-23-053662","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919123053662/doc4.xml","form_type":"4"}},{"id":2190582,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-09T20:34:26.000Z","date":"2022-08-05","kind":"purchase","acquired":true,"shares":250000,"price":20,"value":5000000.0,"ownership":{"direct":true},"balance_after":8684232,"source":{"system":"sec-edgar","filing":"0001209191-22-045014","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919122045014/doc4.xml","form_type":"4"}},{"id":2394081,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":4,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":5,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-15T22:00:58.000Z","date":"2022-02-11","kind":"purchase","acquired":true,"shares":112665,"price":7.1006,"value":799989.099,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James N. Topper and Patrick J. Heron are the sole managing members of FHM LLC. Mr. Topper, Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any."}],"balance_after":1484115,"source":{"system":"sec-edgar","filing":"0001209191-22-009821","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919122009821/doc4.xml","form_type":"4"}},{"id":2562906,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":2,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":3,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":5,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2021-09-21T17:54:32.000Z","date":"2021-09-17","kind":"grant","acquired":true,"shares":1200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Pre-Funded Warrant has no expiration date and is exercisable immediately.  Notwithstanding the foregoing, the Reporting Person shall not be entitled to exercise the Pre-Funded Warrant if it would cause (i) the aggregate number of shares of Common Stock beneficially owned by the Reporting Person, its affiliates and any persons who are members of a Section 13(d) group with the Reporting Person or its affiliates to exceed 9.99% (the \"Maximum Percentage\") of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise, or (ii) the combined voting power of the securities of the Issuer beneficially owned by the Reporting Person and its affiliates and any other persons who are members of a Section 13(d) group with the Reporting Person or its affiliates to exceed the Maximum Percentage of the combined voting power of all of the securities of the Issuer then outstanding following such exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Maximum Percentage can be changed by the holder upon 61 days notice to the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrant has no expiration date and is exercisable immediately.  Notwithstanding the foregoing, the Reporting Person shall not be entitled to exercise the Pre-Funded Warrant if it would cause (i) the aggregate number of shares of Common Stock beneficially owned by the Reporting Person, its affiliates and any persons who are members of a Section 13(d) group with the Reporting Person or its affiliates to exceed 9.99% (the \"Maximum Percentage\") of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise, or (ii) the combined voting power of the securities of the Issuer beneficially owned by the Reporting Person and its affiliates and any other persons who are members of a Section 13(d) group with the Reporting Person or its affiliates to exceed the Maximum Percentage of the combined voting power of all of the securities of the Issuer then outstanding following such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Maximum Percentage can be changed by the holder upon 61 days notice to the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James N. Topper and Patrick J. Heron are the sole managing members of FHM LLC. Mr. Topper, Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any."}],"balance_after":1200000,"derivative":{"exercise_price":0.001,"underlying":"Common Stock","underlying_shares":1200000},"source":{"system":"sec-edgar","filing":"0001209191-21-057010","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919121057010/doc4.xml","form_type":"4"}},{"id":2562905,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":2,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":3,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":5,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-21T17:54:32.000Z","date":"2021-09-17","kind":"disposition_to_issuer","acquired":false,"shares":1200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Frazier Life Sciences VIII, L.P. entered into an Exchange Agreement with the Issuer pursuant to which, Frazier Life Sciences VIII, L.P. exchanged, on a 1:1 basis, 1,200,000 shares of the Issuer's Common Stock for a prefunded warrant to purchase 1,200,000 shares of the Issuer's Common Stock at an exercise price of  $0.001 per share (the \"Pre-Funded Warrant\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James N. Topper and Patrick J. Heron are the sole managing members of FHM LLC. Mr. Topper, Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any."}],"balance_after":1371450,"source":{"system":"sec-edgar","filing":"0001209191-21-057010","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919121057010/doc4.xml","form_type":"4"}},{"id":2715984,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":2,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":3,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":5,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-12T21:37:34.000Z","date":"2021-05-10","kind":"other","acquired":false,"shares":96574,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By FHM Life Sciences VIII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents a pro rata in-kind stock distribution by FHM Life Sciences VIII, L.P. to its limited partners for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held of record by FHM Life Sciences VIII, L.P. The general partner of FHM Life Sciences VIII, L.P. is FHM Life Sciences VIII, L.L.C.  Dr. Topper and Dr. Heron are the sole managing members of FHM Life Sciences VIII, L.L.C. and share voting and investment power of the securities held by FHM Life Sciences VIII, L.P. Dr. Topper and Dr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-032151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919121032151/doc4.xml","form_type":"4"}},{"id":2715983,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":2,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":3,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":5,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-12T21:37:34.000Z","date":"2021-05-10","kind":"other","acquired":true,"shares":96574,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By FHM Life Sciences VIII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Reflects shares of Common Stock received from FLS VIII in the in-kind stock distribution described herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held of record by FHM Life Sciences VIII, L.P. The general partner of FHM Life Sciences VIII, L.P. is FHM Life Sciences VIII, L.L.C.  Dr. Topper and Dr. Heron are the sole managing members of FHM Life Sciences VIII, L.L.C. and share voting and investment power of the securities held by FHM Life Sciences VIII, L.P. Dr. Topper and Dr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":96574,"source":{"system":"sec-edgar","filing":"0001209191-21-032151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919121032151/doc4.xml","form_type":"4"}},{"id":2715982,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":2,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":3,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":5,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-12T21:37:34.000Z","date":"2021-05-10","kind":"other","acquired":false,"shares":2108558,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro rata in-kind stock distribution by Frazier Life Sciences VIII, L.P. (\"FLS VIII\") to its limited partners and general partner for no consideration."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Represents shares held of record by FLS VIII. The general partner of FLS VIII is FHM Life Sciences VIII, L.P., and the general partner of FHM Life Sciences VIII, L.P. is FHM Life Sciences VIII, L.L.C. James Topper and Patrick Heron are the sole managing members of FHM Life Sciences VIII, L.L.C. and share voting and investment power of the securities held by FLS VIII. Dr. Topper and Dr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":8434232,"source":{"system":"sec-edgar","filing":"0001209191-21-032151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919121032151/doc4.xml","form_type":"4"}},{"id":3286296,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-02-06T15:29:42.000Z","date":"2020-02-04","kind":"exercise","acquired":false,"shares":1074467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1074467},"source":{"system":"sec-edgar","filing":"0001209191-20-007100","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919120007100/doc4.xml","form_type":"4"}},{"id":3286295,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-02-06T15:29:42.000Z","date":"2020-02-04","kind":"exercise","acquired":false,"shares":2099019,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2099019},"source":{"system":"sec-edgar","filing":"0001209191-20-007100","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919120007100/doc4.xml","form_type":"4"}},{"id":3286294,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-02-06T15:29:42.000Z","date":"2020-02-04","kind":"exercise","acquired":false,"shares":6360272,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6360272},"source":{"system":"sec-edgar","filing":"0001209191-20-007100","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919120007100/doc4.xml","form_type":"4"}},{"id":3286293,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-06T15:29:42.000Z","date":"2020-02-04","kind":"purchase","acquired":true,"shares":500000,"price":17,"value":8500000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":10542790,"source":{"system":"sec-edgar","filing":"0001209191-20-007100","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919120007100/doc4.xml","form_type":"4"}},{"id":3286292,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-06T15:29:42.000Z","date":"2020-02-04","kind":"exercise","acquired":true,"shares":1074467,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":10042790,"source":{"system":"sec-edgar","filing":"0001209191-20-007100","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919120007100/doc4.xml","form_type":"4"}},{"id":3286291,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-06T15:29:42.000Z","date":"2020-02-04","kind":"exercise","acquired":true,"shares":2099019,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":8968323,"source":{"system":"sec-edgar","filing":"0001209191-20-007100","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919120007100/doc4.xml","form_type":"4"}},{"id":3286290,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-06T15:29:42.000Z","date":"2020-02-04","kind":"exercise","acquired":true,"shares":6360272,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":6869304,"source":{"system":"sec-edgar","filing":"0001209191-20-007100","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919120007100/doc4.xml","form_type":"4"}},{"id":3312445,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":2,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":3,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":4,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-13T15:47:04.000Z","date":"2020-01-09","kind":"sale","acquired":false,"shares":50000,"price":5.0002,"value":250010.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1 to this Form 4"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any."}],"balance_after":1299953,"source":{"system":"sec-edgar","filing":"0001209191-20-003162","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919120003162/doc4.xml","form_type":"4"}},{"id":3690491,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":4,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-01-22T22:14:24.000Z","date":"2019-01-18","kind":"purchase","acquired":true,"shares":145251,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any."}],"balance_after":145251,"derivative":{"exercise_price":12.74,"exercise_date":"2019-01-18","expiration_date":"2024-01-18","underlying":"Common Stock","underlying_shares":145251},"source":{"system":"sec-edgar","filing":"0001209191-19-004783","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000120919119004783/doc4.xml","form_type":"4"}},{"id":3690490,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":4,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-01-22T22:14:24.000Z","date":"2019-01-18","kind":"purchase","acquired":true,"shares":372439,"price":5.37,"value":1999997.43,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any."}],"balance_after":2571450,"source":{"system":"sec-edgar","filing":"0001209191-19-004783","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000120919119004783/doc4.xml","form_type":"4"}},{"id":3800768,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":2,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":3,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":4,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Tranche B Convertible Preferred Stock","published_at":"2018-10-03T01:38:00.000Z","date":"2018-09-28","kind":"exercise","acquired":false,"shares":6651574,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":320898},"source":{"system":"sec-edgar","filing":"0001209191-18-053535","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000120919118053535/doc4.xml","form_type":"4"}},{"id":3800767,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":2,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":3,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":4,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Tranche A Convertible Preferred Stock","published_at":"2018-10-03T01:38:00.000Z","date":"2018-09-28","kind":"exercise","acquired":false,"shares":5212833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":251487},"source":{"system":"sec-edgar","filing":"0001209191-18-053535","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000120919118053535/doc4.xml","form_type":"4"}},{"id":3800766,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":2,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":3,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":4,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-10-03T01:38:00.000Z","date":"2018-09-28","kind":"exercise","acquired":false,"shares":7000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":337707},"source":{"system":"sec-edgar","filing":"0001209191-18-053535","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000120919118053535/doc4.xml","form_type":"4"}},{"id":3800765,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":2,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":3,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":4,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-03T01:38:00.000Z","date":"2018-09-28","kind":"purchase","acquired":true,"shares":375887,"price":15,"value":5638305.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any."}],"balance_after":1349953,"source":{"system":"sec-edgar","filing":"0001209191-18-053535","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000120919118053535/doc4.xml","form_type":"4"}},{"id":3800764,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":2,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":3,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":4,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-03T01:38:00.000Z","date":"2018-09-28","kind":"exercise","acquired":true,"shares":320898,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This number includes an aggregate of 63,974 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any."}],"balance_after":974066,"source":{"system":"sec-edgar","filing":"0001209191-18-053535","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000120919118053535/doc4.xml","form_type":"4"}},{"id":3800763,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":2,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":3,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":4,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-03T01:38:00.000Z","date":"2018-09-28","kind":"exercise","acquired":true,"shares":251487,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any."}],"balance_after":589194,"source":{"system":"sec-edgar","filing":"0001209191-18-053535","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000120919118053535/doc4.xml","form_type":"4"}},{"id":3800762,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":2,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":3,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":4,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-03T01:38:00.000Z","date":"2018-09-28","kind":"exercise","acquired":true,"shares":337707,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any."}],"balance_after":337707,"source":{"system":"sec-edgar","filing":"0001209191-18-053535","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000120919118053535/doc4.xml","form_type":"4"}},{"id":3883183,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":4,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-06-26T16:56:25.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":21946301,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"date","element":"transactionDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences VIII, L.P. (\"FLS-VIII\")  and this report is filed jointly by Frazier Life Sciences VIII, L.P. (\"FLS-VIII L.P.\"), FHM Life Sciences VIII, L.P. (FHM-VIII L.P.\"), FHM Life Sciences VIII, L.L.C. (\"FHM-VIII LLC\") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":795553},"source":{"system":"sec-edgar","filing":"0001104659-18-042315","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042315/a4.xml","form_type":"4"}},{"id":3883182,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":4,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2018-06-26T16:56:25.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":33022786,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"date","element":"transactionDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences VIII, L.P. (\"FLS-VIII\")  and this report is filed jointly by Frazier Life Sciences VIII, L.P. (\"FLS-VIII L.P.\"), FHM Life Sciences VIII, L.P. (FHM-VIII L.P.\"), FHM Life Sciences VIII, L.L.C. (\"FHM-VIII LLC\") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1197076},"source":{"system":"sec-edgar","filing":"0001104659-18-042315","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042315/a4.xml","form_type":"4"}},{"id":3883181,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":4,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2018-06-26T16:56:25.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":28895188,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"date","element":"transactionDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences VIII, L.P. (\"FLS-VIII\")  and this report is filed jointly by Frazier Life Sciences VIII, L.P. (\"FLS-VIII L.P.\"), FHM Life Sciences VIII, L.P. (FHM-VIII L.P.\"), FHM Life Sciences VIII, L.L.C. (\"FHM-VIII LLC\") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1047450},"source":{"system":"sec-edgar","filing":"0001104659-18-042315","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042315/a4.xml","form_type":"4"}},{"id":3883180,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":4,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T16:56:25.000Z","date":"2018-06-25","kind":"purchase","acquired":true,"shares":150000,"price":16,"value":2400000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"On June 25, 2018, FLS-VIII purchased 150,000 shares of common stock of the Issuer at a price of $16.00 per share pursuant to an underwritten public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences VIII, L.P. (\"FLS-VIII\")  and this report is filed jointly by Frazier Life Sciences VIII, L.P. (\"FLS-VIII L.P.\"), FHM Life Sciences VIII, L.P. (FHM-VIII L.P.\"), FHM Life Sciences VIII, L.L.C. (\"FHM-VIII LLC\") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein."}],"balance_after":3190079,"source":{"system":"sec-edgar","filing":"0001104659-18-042315","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042315/a4.xml","form_type":"4"}},{"id":3883179,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":4,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T16:56:25.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":795553,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences VIII, L.P. (\"FLS-VIII\")  and this report is filed jointly by Frazier Life Sciences VIII, L.P. (\"FLS-VIII L.P.\"), FHM Life Sciences VIII, L.P. (FHM-VIII L.P.\"), FHM Life Sciences VIII, L.L.C. (\"FHM-VIII LLC\") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein."}],"balance_after":3040079,"source":{"system":"sec-edgar","filing":"0001104659-18-042315","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042315/a4.xml","form_type":"4"}},{"id":3883178,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":4,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T16:56:25.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":1197076,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences VIII, L.P. (\"FLS-VIII\")  and this report is filed jointly by Frazier Life Sciences VIII, L.P. (\"FLS-VIII L.P.\"), FHM Life Sciences VIII, L.P. (FHM-VIII L.P.\"), FHM Life Sciences VIII, L.L.C. (\"FHM-VIII LLC\") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein."}],"balance_after":2244526,"source":{"system":"sec-edgar","filing":"0001104659-18-042315","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042315/a4.xml","form_type":"4"}},{"id":3883177,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":4,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T16:56:25.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":1047450,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences VIII, L.P. (\"FLS-VIII\")  and this report is filed jointly by Frazier Life Sciences VIII, L.P. (\"FLS-VIII L.P.\"), FHM Life Sciences VIII, L.P. (FHM-VIII L.P.\"), FHM Life Sciences VIII, L.L.C. (\"FHM-VIII LLC\") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein."}],"balance_after":1047450,"source":{"system":"sec-edgar","filing":"0001104659-18-042315","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042315/a4.xml","form_type":"4"}}]}